iRhythm Technologies (IRTC)

• Market cap: $3.74B
• 1 day: 6.01%
• 5 days: 5.92%
• 1 month: 9.87%
• 3 months: 61.62%
• 6 months: 69.01%
• Year to date: 33.54%
• 1 year: 6.72%
• 5 years: 35.73%
• 10 years: 358.50%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.

Employees: 2,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

15% more capital invested

Capital invested by funds: $2.62B [Q3] → $3.02B (+$402M) [Q4]

3.14% less ownership

Funds ownership: 112.77% [Q3] → 109.63% (-3.14%) [Q4]

8% less funds holding

Funds holding: 239 [Q3] → 220 (-19) [Q4]

13% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 80

24% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 50

56% less call options, than puts

Call options by funds: $11.4M | Put options by funds: $25.8M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $104 13% downside
• Avg. target: $132 10% upside
• High target: $152 27% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

Truist Securities Richard Newitter 77% 1-year accuracy 33 / 43 met price target	21% upside $145	Buy Maintained	21 Feb 2025
Wells Fargo Nathan Treybeck 50% 1-year accuracy 2 / 4 met price target	13% downside $104	Equal-Weight Maintained	21 Feb 2025
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target	16% upside $138	Buy Maintained	21 Feb 2025
Oppenheimer Suraj Kalia 67% 1-year accuracy 16 / 24 met price target	0% upside $120	Outperform Maintained	8 Jan 2025
Canaccord Genuity William Plovanic 67% 1-year accuracy 33 / 49 met price target	27% upside $152	Buy Maintained	9 Dec 2024